Zevra Therapeutics (ZVRA) Return on Invested Capital (2015 - 2026)

Zevra Therapeutics has reported Return on Invested Capital for 12 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.0% in Q1 2022, with the low at 0.02% in Q2 2024.
• Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.0% in 2023.
• Annual changes were most pronounced in 2022 — Return on Invested Capital slipped 1 bps — and 2025, when it gained 2 bps.
• Zevra Therapeutics' Return on Invested Capital stood at 0.0% in 2022, then sank by 442 bps to 0.01% in 2023, then tumbled by 68 bps to 0.01% in 2024, then jumped by 76 bps to 0.0% in 2025, then surged by 92 bps to 0.0% in 2026.
• The last three Return on Invested Capital figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.